CoChat

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders

Uhlenhuth, E. H., Balter, Mitchell B., Ban, Thomas A., Yang, Kenneth · 1999 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-199912002-00005

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 4

  1. Woods, 1987, Pharmacol Rev, 39, 251
  2. Woods, 1992, Pharmacol Rev, 44, 151
  3. 1993, eports, 1, 19
  4. Uhlenhuth, 1995, Psychopharmacol Bull, 31, 289

Cited by

See all 80

Metadata

Authors
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K.
Affiliations
  • University of New Mexico (US)
  • Tufts University (US)
  • Vanderbilt University (US)
Corresponding author
Uhlenhuth, E. H.
Venue
Journal of Clinical Psychopharmacology
Published
1999-12
Volume
19
Issue
6 Suppl 2
Pages
23S-29S
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1979163345
Cited by
80
References
16
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2021: 1 · 2020: 23 · 2019: 6 · 2018: 1 · 2017: 5 · 2014: 2 · 2013: 1 · 2012: 3
FWCI
5.14
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
benzodiazepines, anxiety disorders, abuse liability, long-term benzodiazepine use, withdrawal symptoms, benzodiazepine tapering, abrupt discontinuation, half-life, expert consensus, depressive disorders
MeSH terms
Anxiety Disorders, Benzodiazepines, Depression, Humans, Surveys and Questionnaires, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. https://app.cochat.ai/papers/10.1097/00004714-199912002-00005
The paper
Uhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999). International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199912002-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.